Source: Spectral Medical Inc.
  • Spectral Medical (EDT) subsidiary Dialco Medical, and distribution partner Marathon Medical Corporation, have been awarded a five-year contract with the U.S. Department of Veterans Affairs
  • Dialco and Marathon Medical will provide SAMI CRRT (chronic renal replacement therapy) dialysis devices and associated maintenance services
  • Marathon Medical is a leading medical supply distribution company and veteran-owned small business
  • Spectral is a Phase 3 company seeking U.S. FDA approval for its unique product for the treatment of patients with septic shock
  • Spectral Medical Inc. (EDT) is up 1.89 per cent on the day, trading at C$0.54 per share at 1:15 pm ET

Spectral Medical (EDT) subsidiary Dialco Medical, and distribution partner Marathon Medical Corporation, have been awarded a five-year contract.

Under the Indefinite Delivery/Indefinite Quantity (IDIQ) contract, Dialco and Marathon Medical will provide SAMI CRRT (chronic renal replacement therapy) dialysis devices and associated maintenance services to the United States Department of Veterans Affairs’ (VA) national healthcare system.

The United States Department of Veterans Affairs is a government agency responsible for providing healthcare and other services to veterans. The VA initiated the solicitation of bids in order to streamline the purchasing and contract process, as well as provide enhanced product choices for VA healthcare professionals. Upon review, SAMI was selected and added to the approved product list for VA healthcare facilities nationwide.

Sam Amory, President of Dialco, commented on the news.

“We are proud to have our SAMI device selected by the VA and added to the approved product list for healthcare professionals. This selection followed an evaluation of our technology, and successful demonstration of our ability to meet the stringent specifications of the VA, including safety, efficacy, and ease of use. Importantly, our open platform design offers the opportunity for RRT cost control and therapy customization. SAMI also provides clear visuals with an easy-to-read display and rapid set up, which reduces the burden on healthcare staff. Marathon is an ideal partner on this five year IDIQ contract, as they have a successful track record supporting the market with new medical devices and a reputation for timely delivery of supplies. We believe the receipt of this contract award is an important milestone towards accelerating the commercial rollout of our SAMI device.”

Jon Landis, Chief Operating Officer of Marathon, added,

“We are excited to partner with Dialco to improve healthcare outcomes for America’s veterans. SAMI provides an alternative, user friendly and cost effective option to healthcare providers, medical centers and hospitals. We are honored to receive this important contract and look forward to supporting VA medical centers with this innovative healthcare solution.”

Marathon Medical is a leading medical supply distribution company and veteran-owned small business, with a focus on federal government customers. Marathon Medical works with a variety of manufacturers to provide solutions for every department within the hospital.

Spectral is a Phase 3 company seeking U.S. FDA approval for its unique product for the treatment of patients with septic shock, Toraymyxin. 

Spectral Medical Inc. (EDT) is up 1.89 per cent on the day, trading at C$0.54 per share at 1:15 pm ET.


More From The Market Online

Calian scores $23 million Canadian Armed Forces contract

Calian Group Ltd. (TSX:CGY) has been awarded a $17 million contract by the Canadian Armed Forces’ Canadian Forces Health Services Group.

Unsung profits: Three microcap stocks with a strong case for value

A key factor behind picking winning microcap value stocks is identifying dislocations between company performance and market perception.

This life sciences company is gearing up to treat long COVID  

Revive Therapeutics (CSE:RVV), a Toronto-based company, has immense potential to capitalize on treating long COVID symptoms.

Theralase advances cancer research after private placement

Theralase Technologies (TSXV:TLT) closes a non-brokered private placement offering of 4.1 million shares for gross proceeds of C$750,200.